Share this page!

Mac n’ Chise 🧬🦠🧫 Profile picture
Twitter logo
14 Apr, 5 tweets, 2 min read
Preclinical data shows Moderna’s variant-specific booster vaccine candidates (mRNA-1273.351 and mRNA-1273.211) increase neutralizing titers against SARS-CoV-2 variants of concern. The data is absolutely stunning! Preprint can be found here:
biorxiv.org/content/10.110…
mRNA-1273.351 encodes for the S protein found in the B.1.351 lineage and mRNA-1273.211 comprising a 1:1 mix of mRNA-1273 and mRNA-1273.351. Both vaccines were evaluated as a 2-dose primary series in mice.
mRNA-1273.351 was also evaluated as a booster dose in animals previously vaccinated with 2-doses of mRNA-1273. The results demonstrate that a primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against the B.1.351 lineage, while
mRNA-1273.211 was most effective at providing broad cross-variant neutralization in mice. In addition, these results demonstrated a third dose of mRNA-1273.351 significantly increased both wild-type and B.1.351-specific neutralization titers.
Both mRNA-1273.351 and mRNA-1273.211 are currently being evaluated in additional pre-clinical challenge models and in phase 1/2 clinical studies.
investors.modernatx.com/news-releases/…

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Mac n’ Chise 🧬🦠🧫

Mac n’ Chise 🧬🦠🧫 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @sailorrooscout

Mac n’ Chise 🧬🦠🧫 Profile picture
16 Apr
Please keep in mind variant B.1.167 out of India is still considered a variant of interest, not a variant of concern. B.1.167 lineage isolates are actually common in India and while it carries mutations E484Q and L452R, it does not carry any deletion mutations we see in current
variants of concern. Lastly, this variant was present in India last year, and while media highlights the presence of it in the UK as recent, it’s first occurrence in the UK dates back to February 22nd. The claims that it bypasses T-cell immunity are NOT currently substantiated.
The most important thing as always is to get vaccinated and control its spread. Let’s stay focused. Current variants of concern are: B.1.351, P.1, B.1.1.7, and B.1.427/B.1.429.
Read 4 tweets
Mac n’ Chise 🧬🦠🧫 Profile picture
13 Apr
Please be aware that out of 6.8M+ doses of the J&J vaccine that have been administered in the U.S., 6 cases of a rare & severe type of blood clot in individuals after receiving the vaccine have been reported. Right now, these adverse events appear to be extremely rare.
With this said, in the U.S., we have mRNA (Moderna & Pfizer) vaccines available so please do not let this deter you from getting vaccinated in the meantime. All 6 cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination.
I want everyone to put this in perspective and try to process this rationally. 6 cases out of 6.8M+ doses administered (0.00000088). They’re looking into this out of an abundance of caution. You are MORE likely to suffer from blood clots from being infected with SARS-CoV-2.
Read 6 tweets
Mac n’ Chise 🧬🦠🧫 Profile picture
10 Apr
Wanted to clear this up. First, please remember that vaccines are preventives and NOT cures. One can still contract the virus once vaccinated and as long as it prevents them from facing severe disease and worse, it is still doing what it is supposed to.
timesofisrael.com/real-world-isr…
Secondly, what is important to know about this study is that most infections were from B.1.1.7, with only 8 cases being B.1.351. After two doses, extremely high effectiveness against B.1.1.7 took effect. While they observed reduced effectiveness against B.1.351, they also saw it
did not spread in Israel. In other words, B.1.1.7 is keeping B.1.351 “in check” which is what a lot of scientists predicted months ago when these variants came onto the scene. This is a good thing. Why? We know the vaccines are HIGHLY effective against B.1.1.7
Read 6 tweets
Mac n’ Chise 🧬🦠🧫 Profile picture
8 Apr
Encouraging studies! 🧵
An analysis of cross-reactive viral binding and neutralization of emerging SARS-CoV-2 variants shows Novavax’s and Moderna’s vaccines elicit immune responses that are effective against variants B.1.429 (CA) and B.1.351 (S. Africa).
nejm.org/doi/full/10.10…
Patients previously infected with SARS-CoV-2 received Pfizer’s vaccine. Before vaccination, they had neutralizing activity against variants B.1.1.7 & P.1 but not B.1.351. AFTER one dose, neutralizing activity against ALL variants increased substantially!
nejm.org/doi/full/10.10…
Convalescent serum from those who recovered from an infection with SARS-CoV-2 variant B.1.351 showed potent neutralization of D614G (original), as well as variants B.1.351 (S. Africa) AND P.1 (Brazil). Booster vaccines may just seal the deal if needed!
nejm.org/doi/full/10.10…
Read 9 tweets
Mac n’ Chise 🧬🦠🧫 Profile picture
5 Apr
We know individuals who recover from SARS-CoV-2 infections develop effective T-cell immunity. A new study in Nature finds individuals are able to gain T-cell memory in the absence of a detectable infection simply from exposure!
nature.com/articles/s4146…
Here researchers reported virus-specific CD4+ and CD8+ T-cell memory in recovered COVID-19 patients and close contacts. Data showed that the memory CD4+ and CD8+ T cells of 94.44% and 83.33%, respectively, of the COVID-19 patients successfully underwent expansion.
Their results indicated that most of the recovered COVID-19 patients had developed effective T-cell memory pools against SARS-CoV-2 and their close contacts to a lesser degree. The proliferation capacity, size and quality of T-cell responses in close contacts were also readily
Read 6 tweets
Mac n’ Chise 🧬🦠🧫 Profile picture
2 Apr
According to the CDC, those who are fully vaccinated can travel “at low risk to themselves,” both within the United States and internationally, but they must continue to take precautions like wearing a mask in public, avoiding crowds, maintaining social distancing.
Vaccinated individuals do not need to get a coronavirus test before arriving in another country, unless required to do so by authorities at the destination, and they do not need to quarantine after returning to the United States unless required to do so by local jurisdictions.
Vaccinated travelers should have a negative result from a coronavirus test before boarding a flight back to the United States, and they should get tested against three to five days after their return home. The recommendations do not alter the guidelines for the unvaccinated.
Read 4 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

Like this author's thread?

Get emails when @sailorrooscout has new unrolls!

Check out other threads from @sailorrooscout!

Read all threads by @sailorrooscout